Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital began coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research report released on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 price target on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a research note on Monday, September 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $6.80.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $1.46 on Monday. The stock’s 50 day simple moving average is $1.99 and its 200-day simple moving average is $2.08. The company has a market cap of $109.50 million, a PE ratio of -1.53 and a beta of 2.25. Context Therapeutics has a 1-year low of $0.77 and a 1-year high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, equities research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of hedge funds have recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new position in Context Therapeutics during the third quarter worth about $89,000. Renaissance Technologies LLC raised its position in shares of Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after buying an additional 25,300 shares during the period. State Street Corp lifted its holdings in Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares during the last quarter. Opaleye Management Inc. grew its position in Context Therapeutics by 13.7% in the first quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock worth $1,530,000 after acquiring an additional 133,357 shares during the period. Finally, Affinity Asset Advisors LLC grew its position in Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after acquiring an additional 1,290,323 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.